Free Trial
→ PH: Do THESE 4 things to your bank account now … (From Weiss Ratings) (Ad)tc pixel Free BPTH Stock Alerts

Bio-Path (BPTH) Competitors

Bio-Path logo
$0.04 0.00 (0.00%)
As of 05/22/2026 03:59 PM Eastern
Compare

BPTH vs. SLXN, WINT, EVFM, HEPA, and CERO

Should you buy Bio-Path stock or one of its competitors? MarketBeat compares Bio-Path with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bio-Path include Silexion Therapeutics (SLXN), Windtree Therapeutics (WINT), Evofem Biosciences (EVFM), Hepion Pharmaceuticals (HEPA), and CERo Therapeutics (CERO). These companies are all part of the "pharmaceutical products" industry.

How does Bio-Path compare to Silexion Therapeutics?

Silexion Therapeutics (NASDAQ:SLXN) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

11.0% of Silexion Therapeutics shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 5.0% of Silexion Therapeutics shares are owned by company insiders. Comparatively, 0.7% of Bio-Path shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Silexion Therapeutics is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silexion TherapeuticsN/AN/A-$11.91M-$8.05N/A
Bio-PathN/AN/A-$16.08M-$1.06N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Silexion Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Bio-Path
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Silexion Therapeutics' return on equity of -516.86% beat Bio-Path's return on equity.

Company Net Margins Return on Equity Return on Assets
Silexion TherapeuticsN/A -516.86% -176.68%
Bio-Path N/A -2,842.40%-337.48%

In the previous week, Silexion Therapeutics had 2 more articles in the media than Bio-Path. MarketBeat recorded 2 mentions for Silexion Therapeutics and 0 mentions for Bio-Path. Silexion Therapeutics' average media sentiment score of 0.49 beat Bio-Path's score of 0.00 indicating that Silexion Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Silexion Therapeutics Neutral
Bio-Path Neutral

Silexion Therapeutics has a beta of -0.29, suggesting that its stock price is 129% less volatile than the broader market. Comparatively, Bio-Path has a beta of -0.29, suggesting that its stock price is 129% less volatile than the broader market.

Summary

Silexion Therapeutics beats Bio-Path on 9 of the 11 factors compared between the two stocks.

How does Bio-Path compare to Windtree Therapeutics?

Bio-Path (NASDAQ:BPTH) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

Bio-Path has a beta of -0.29, meaning that its share price is 129% less volatile than the broader market. Comparatively, Windtree Therapeutics has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market.

Windtree Therapeutics' return on equity of -207.34% beat Bio-Path's return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-PathN/A -2,842.40% -337.48%
Windtree Therapeutics N/A -207.34%-50.19%

Bio-Path is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-PathN/AN/A-$16.08M-$1.06N/A
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A

In the previous week, Bio-Path's average media sentiment score of 0.00 equaled Windtree Therapeutics'average media sentiment score.

Company Overall Sentiment
Bio-Path Neutral
Windtree Therapeutics Neutral

5.7% of Bio-Path shares are held by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are held by institutional investors. 0.7% of Bio-Path shares are held by company insiders. Comparatively, 0.2% of Windtree Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Windtree Therapeutics beats Bio-Path on 6 of the 8 factors compared between the two stocks.

How does Bio-Path compare to Evofem Biosciences?

Bio-Path (NASDAQ:BPTH) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by insiders. Comparatively, 0.0% of Evofem Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Evofem Biosciences has higher revenue and earnings than Bio-Path. Evofem Biosciences is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-PathN/AN/A-$16.08M-$1.06N/A
Evofem Biosciences$11.39M0.09$52.98M-$0.07N/A

Bio-Path has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat Bio-Path's return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-PathN/A -2,842.40% -337.48%
Evofem Biosciences -46.42%-91.97%-61.93%

In the previous week, Bio-Path's average media sentiment score of 0.00 equaled Evofem Biosciences'average media sentiment score.

Company Overall Sentiment
Bio-Path Neutral
Evofem Biosciences Neutral

Bio-Path has a beta of -0.29, meaning that its stock price is 129% less volatile than the broader market. Comparatively, Evofem Biosciences has a beta of -1.32, meaning that its stock price is 232% less volatile than the broader market.

Summary

Evofem Biosciences beats Bio-Path on 6 of the 10 factors compared between the two stocks.

How does Bio-Path compare to Hepion Pharmaceuticals?

Hepion Pharmaceuticals (NASDAQ:HEPA) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Hepion Pharmaceuticals' return on equity of -812.56% beat Bio-Path's return on equity.

Company Net Margins Return on Equity Return on Assets
Hepion PharmaceuticalsN/A -812.56% -207.31%
Bio-Path N/A -2,842.40%-337.48%

In the previous week, Hepion Pharmaceuticals' average media sentiment score of 0.00 equaled Bio-Path'saverage media sentiment score.

Company Overall Sentiment
Hepion Pharmaceuticals Neutral
Bio-Path Neutral

17.2% of Hepion Pharmaceuticals shares are held by institutional investors. Comparatively, 5.7% of Bio-Path shares are held by institutional investors. 0.1% of Hepion Pharmaceuticals shares are held by company insiders. Comparatively, 0.7% of Bio-Path shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Bio-Path is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hepion PharmaceuticalsN/AN/A-$48.93M-$72.15N/A
Bio-PathN/AN/A-$16.08M-$1.06N/A

Hepion Pharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Bio-Path has a beta of -0.29, suggesting that its share price is 129% less volatile than the broader market.

Summary

Hepion Pharmaceuticals beats Bio-Path on 5 of the 8 factors compared between the two stocks.

How does Bio-Path compare to CERo Therapeutics?

Bio-Path (NASDAQ:BPTH) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

CERo Therapeutics has a consensus price target of $30.00, indicating a potential upside of 146,241.46%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CERo Therapeutics is more favorable than Bio-Path.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Path
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
CERo Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Bio-Path has a beta of -0.29, suggesting that its share price is 129% less volatile than the broader market. Comparatively, CERo Therapeutics has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market.

Bio-Path is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-PathN/AN/A-$16.08M-$1.06N/A
CERo TherapeuticsN/AN/A-$8.30M-$71.01N/A

CERo Therapeutics' return on equity of 0.00% beat Bio-Path's return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-PathN/A -2,842.40% -337.48%
CERo Therapeutics N/A N/A -209.40%

5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by company insiders. Comparatively, 0.4% of CERo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, CERo Therapeutics had 1 more articles in the media than Bio-Path. MarketBeat recorded 1 mentions for CERo Therapeutics and 0 mentions for Bio-Path. Bio-Path's average media sentiment score of 0.00 equaled CERo Therapeutics'average media sentiment score.

Company Overall Sentiment
Bio-Path Neutral
CERo Therapeutics Neutral

Summary

CERo Therapeutics beats Bio-Path on 9 of the 11 factors compared between the two stocks.

Get Bio-Path News Delivered to You Automatically

Sign up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BPTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BPTH vs. The Competition

Export
MetricBio-PathPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$422K$927.43M$6.46B$12.34B
Dividend YieldN/A4.84%2.76%5.28%
P/E Ratio-0.041.4621.0025.66
Price / SalesN/A119.63562.1886.31
Price / CashN/A20.0743.4956.67
Price / Book0.067.5910.417.14
Net Income-$16.08M-$3.64M$3.57B$335.98M
7 Day PerformanceN/A3.01%6.40%4.11%
1 Month PerformanceN/A76.62%3.54%2.52%
1 Year PerformanceN/A126.61%34.14%35.04%

Bio-Path Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BPTH
Bio-Path
N/A$0.04
flat		N/A-77.2%$422KN/AN/A10
SLXN
Silexion Therapeutics
1.1005 of 5 stars		$0.27
-1.6%		N/A-96.8%$910KN/AN/AN/A
WINT
Windtree Therapeutics
N/A$0.02
+7.7%		N/A-98.2%$882KN/AN/A30
EVFM
Evofem Biosciences
N/A$0.01
-3.1%		N/A-25.3%$835K$11.39MN/A120
HEPA
Hepion Pharmaceuticals
N/A$0.07
-23.0%		N/A+14.9%$819KN/AN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BPTH) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel
Skip the Line Opportunity: The SpaceX IPO
Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...
Brownstone Research | Sponsoredtc pixel